Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
36.66
-1.66 (-4.33%)
Nov 21, 2025, 11:59 AM HKT
-4.33%
Market Cap45.34B
Revenue (ttm)7.17B
Net Income (ttm)669.02M
Shares Outn/a
EPS (ttm)0.78
PE Ratio67.77
Forward PE34.05
Dividend0.32 (0.82%)
Ex-Dividend DateJun 12, 2025
Volume1,720,000
Average Volume2,185,624
Open37.96
Previous Close38.32
Day's Range36.08 - 38.08
52-Week Range22.30 - 60.60
Beta0.82
RSI33.56
Earnings DateOct 28, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.